Vroom, Vroom

This company’s machine learning programs are making driving in Houston safer — and cheaper

This entrepreneur says the future of driving is using smart tech on a subscription-based business model. Pexels

Two thousand years ago, in ancient Rome, the primary mode of transportation was an intelligent one: the horse. The Latin word "currus" was the inspiration for Alex Colosivschi when it came to naming his business, Currux.

"We chose this name because we believe in a future where cars and actually most modes of transportation will be intelligent, like horses," he explains. "And so it's a great name considering our focus on the future of mobility and machine learning."

The change from "s" to "x" at the end of the word allowed Colosivschi to trademark the name.

The entrepreneur, whose career was focused on energy finance until starting the new company in 2017, came up with the idea for Currux while walking in his Rice Village neighborhood. He realized that despite the green surroundings, he was choked by the smell of engine exhaust.

"I started with thinking about the future of energy and how the industry will adapt to a world of electric, autonomous and shared mobility, and the need to reduce CO2 emissions," he says.

His goal is an ambitious one: With Currux, Colosivschi hopes to not only reduce the cost and carbon footprint of owning a car, but also the accident rates. How? Currux itself is a long-term automobile subscription service. Colosivschi says to think of it as a long-term rental or a more flexible version of a lease. The car is delivered through an app and there is no commitment at the end of the subscription. Regular maintenance is included and the company is on the way to providing insurance, too.

It's also possible to share a car or fleet of cars with friends, assuring that your vehicle is only touched by people you know. This will be even more true when autonomous driving technology allows the car to go from subscriber to subscriber without a human in between.

"With the advent of digital shopping, we believe subscriptions will become the primary way that people get a car," Colosivschi predicts.

This will save clients money, but the ultimate goal is much bigger. Colosivschi wants to reduce air pollution. This will happen naturally with having fewer, mostly electric, cars on the road thanks to vehicle sharing, but another technology will also aid in the fight.

Currux Vision, which closely followed Currux in development, is a smartphone-based driver assistance program. It will help lower fuel consumption and reduce accident rates by "proactively coaching the driver on best driving practices," says Colosivschi.

"Just by slowing down and driving in a less aggressive manner, we can significantly reduce fuel consumption and more importantly prevent accidents from happening."

If you've driven or ridden in a Tesla, you've seen similar technology in action. Computer vision creates accident warnings and tracks how you handle your vehicle on the road. Yep, it's AI for your phone, which also incorporates GPS tracking, navigation and driver profile scoring.

"This set of functionalities normally require three or four different types of hardware and software systems and many thousands of dollars in expense per each car," explains Colosivschi.

But Currux Vision only requires that the user install the app, have a car-mounted phone holder with an unobstructed view of the road, and pay $4.99 each month for the technology.

Both these apps were created by Currux's own technical team, based mostly in Ukraine. As the company expands, Colosivschi has plans to significantly grow the Galleria-area Houston team, which is currently just a few employees strong.

But Colosivschi is ready for big growth. Currently, Currux is available only in Houston, but other U.S. cities will follow soon. As an energy industry lifer, the entrepreneur is also primed for significant changes not only to how we drive, but how we consume energy.

"The age of the internal combustion engine and automobile ushered in the age of oil. The age of lithium ion batteries, machine learning and digitization of transaction mediums similarly will have profound effects for both transportation and energy sectors," he predicts. He's confident that Currux can grow with those sea changes. And he's ready to help transform the world, starting with Houston.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News